Verrica Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell VRCA and other ETFs, options, and stocks.

About VRCA

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. 

CEO
Jayson M. Rieger
CEOJayson M. Rieger
Employees
76
Employees76
Headquarters
West Chester, Pennsylvania
HeadquartersWest Chester, Pennsylvania
Founded
2013
Founded2013
Employees
76
Employees76

VRCA Key Statistics

Market cap
108.05M
Market cap108.05M
Price-Earnings ratio
-6.06
Price-Earnings ratio-6.06
Dividend yield
Dividend yield
Average volume
127.97K
Average volume127.97K
High today
$6.90
High today$6.90
Low today
$6.27
Low today$6.27
Open price
$6.85
Open price$6.85
Volume
81.59K
Volume81.59K
52 Week high
$9.82
52 Week high$9.82
52 Week low
$3.28
52 Week low$3.28

Stock Snapshot

The current Verrica Pharmaceuticals(VRCA) stock price is $6.27, with a market capitalization of 108.05M. The stock trades at a price-to-earnings (P/E) ratio of -6.06.

On 2026-05-17, Verrica Pharmaceuticals(VRCA) stock moved within a range of $6.27 to $6.90. With shares now at $6.27, the stock is trading 0.0% above its intraday low and -9.1% below the session's peak.

Trading activity shows a volume of 81.59K, compared to an average daily volume of 127.97K.

Over the past 52 weeks, Verrica Pharmaceuticals(VRCA) stock has traded between a high of $9.82 and a low of $3.28.

Over the past 52 weeks, Verrica Pharmaceuticals(VRCA) stock has traded between a high of $9.82 and a low of $3.28.

VRCA News

TipRanks 3d
Verrica Pharmaceuticals Earnings Call Highlights Growth, Strain

Verrica Pharmaceuticals ((VRCA)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data...

Seeking Alpha 4d
Verrica targets COVE-3 initiation by mid-2026 as Q1 dispensed YCANTH units rise 12.1% sequentially

Earnings Call Insights Verrica targets COVE-3 initiation by mid-2026 as Q1 dispensed YCANTH units rise 12.1% sequentially May 12, 2026, 9:42 PM ET Verrica Pharm...

Verrica targets COVE-3 initiation by mid-2026 as Q1 dispensed YCANTH units rise 12.1% sequentially
TipRanks 5d
Verrica Pharmaceuticals reports Q1 adjusted EPS (41c), consensus (59c)

Reports Q1 revenue $5.02M, consensus $4.52M. “Our first quarter performance reflects accelerating growth in market demand for YCANTH as the new standard of care...

More VRCA News

Nasdaq 5d
Verrica Pharmaceuticals Inc. Reports Q1 Loss, Tops Revenue Estimates

Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to l...

Verrica Pharmaceuticals Inc. Reports Q1 Loss, Tops Revenue Estimates

People also own

Based on the portfolios of people who own VRCA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.